A new meta-analysis of more than 6000 studies shows that oral contraceptives significantly reduce the risk of ovarian cancer. The risk reduction increases proportionally with duration of use.
See the abstract here
Related Topics
OCRA’s Advocate’s Corner: October 2026
Written by Julia Thayer, OCRA’s Associate Director, Advocacy September was an especially busy month at Ovarian Cancer Research Alliance (OCRA), filled with awareness activities, OCRA’s International Gynecologic Cancer Conference®, and more. But our work continues year-round. 2027 Advocate Leaders Program Draws More Than 100 New Applicants Preparations are already underway for the 2027 Advocate Leaders Program, … Continued
OCRA Sponsors NCCN Guidelines for Cervical, Ovarian, and Uterine Cancer Patients
This article was updated in October 2026 to reflect NCCN’s release of the 2026 Guidelines for Ovarian Cancer Patients. OCRA is a proud sponsor of the 2026 Patient Guidelines for Ovarian Cancer, Cervical Cancer, and Uterine Cancer. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful guides for anyone newly diagnosed … Continued
OCRA’s Rivkin Ovarian Cancer Research Symposium Convenes A Scientific Community Ready to Accelerate Progress
Researchers, clinicians, and advocates gather to share findings and build collaborations More than 375 researchers, clinicians, and advocates from across the ovarian cancer community gathered in Philadelphia for the 16th Biennial Rivkin Ovarian Cancer Research Symposium, presented for the first time by Ovarian Cancer Research Alliance (OCRA), from October 16-18. Founded in 1996 by the … Continued